PULMOZYME dornase alfa

Drug Class

Recombinant human deoxyribonuclease I (rhDNase)

Mechanism

Cleaves extracellular DNA in the purulent secretions of cystic fibrosis patients, reducing sputum viscoelasticity and improving airway clearance.

Approved Indication

In conjunction with standard therapies for the management of cystic fibrosis patients to improve pulmonary function.

What This Means For Patients

PULMOZYME is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (1993) — Sources

Pivotal Clinical Evidence

• Fuchs et al., 1994 — Fuchs et al., N Engl J Med 1994 — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103770s5186lbl.pdf